TCW Group Inc. Sells 350,713 Shares of IQVIA Holdings Inc. (NYSE:IQV)

TCW Group Inc. lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 67.5% during the 4th quarter, HoldingsChannel reports. The firm owned 168,964 shares of the medical research company’s stock after selling 350,713 shares during the period. TCW Group Inc.’s holdings in IQVIA were worth $39,099,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Norges Bank purchased a new position in shares of IQVIA during the 4th quarter valued at $383,705,000. Eagle Asset Management Inc. bought a new stake in IQVIA in the 3rd quarter valued at $102,982,000. iA Global Asset Management Inc. increased its holdings in IQVIA by 1,225.3% in the 3rd quarter. iA Global Asset Management Inc. now owns 320,271 shares of the medical research company’s stock valued at $63,013,000 after acquiring an additional 296,105 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of IQVIA by 2,765.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 271,316 shares of the medical research company’s stock worth $53,381,000 after buying an additional 261,848 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of IQVIA by 33.4% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,039,436 shares of the medical research company’s stock worth $240,505,000 after buying an additional 260,271 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on IQV shares. SVB Leerink started coverage on shares of IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 price target on the stock. Evercore ISI lowered their price objective on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. Robert W. Baird lowered their price objective on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research report on Friday, May 3rd. Barclays upped their price target on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, Truist Financial lowered their price target on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $257.57.

IQVIA Stock Performance

IQVIA stock traded up $1.06 during mid-day trading on Thursday, reaching $227.09. 788,115 shares of the company traded hands, compared to its average volume of 957,522. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a market capitalization of $41.38 billion, a price-to-earnings ratio of 30.87, a price-to-earnings-growth ratio of 2.09 and a beta of 1.52. The firm’s fifty day moving average is $238.14 and its two-hundred day moving average is $228.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.